- Home
- IXHL vs IFRX Comparison
IXHL vs IFRX Comparison
Compare IXHL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- IFRX
- Stock Information
- Founded
- IXHL 2001
- IFRX 2007
- Country
- IXHL Australia
- IFRX Germany
- Employees
- IXHL N/A
- IFRX N/A
- Industry
- IXHL
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- IFRX Health Care
- Exchange
- IXHL Nasdaq
- IFRX Nasdaq
- Market Cap
- IXHL 49.1M
- IFRX 53.5M
- IPO Year
- IXHL N/A
- IFRX 2017
- Fundamental
- Price
- IXHL $0.44
- IFRX $1.43
- Analyst Decision
- IXHL
- IFRX Strong Buy
- Analyst Count
- IXHL 0
- IFRX 5
- Target Price
- IXHL N/A
- IFRX $7.40
- AVG Volume (30 Days)
- IXHL 36.4M
- IFRX 492.5K
- Earning Date
- IXHL 11-13-2025
- IFRX 11-07-2025
- Dividend Yield
- IXHL N/A
- IFRX N/A
- EPS Growth
- IXHL N/A
- IFRX N/A
- EPS
- IXHL N/A
- IFRX N/A
- Revenue
- IXHL $86,000.00
- IFRX $191,224.00
- Revenue This Year
- IXHL $1,188.37
- IFRX N/A
- Revenue Next Year
- IXHL N/A
- IFRX $1,216.24
- P/E Ratio
- IXHL N/A
- IFRX N/A
- Revenue Growth
- IXHL 616.67
- IFRX 54.36
- 52 Week Low
- IXHL $0.08
- IFRX $0.71
- 52 Week High
- IXHL $3.12
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- IXHL 41.95
- IFRX 55.06
- Support Level
- IXHL $0.43
- IFRX $1.29
- Resistance Level
- IXHL $0.50
- IFRX $1.44
- Average True Range (ATR)
- IXHL 0.07
- IFRX 0.14
- MACD
- IXHL -0.01
- IFRX -0.00
- Stochastic Oscillator
- IXHL 14.47
- IFRX 48.84
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.